XOMA Royalty Corporation

XOMAP

$24.98

+0.00%+$0.00

High—

Low—

52W High-9.6%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Loading chart…

AI analysis

XOMA Royalty Corporation is showing mixed intraday momentum with consolidation near key moving averages and heightened sensitivity to liquidity shifts.

Upside confirmation strengthens on sustained reclaim above short-term trend anchors.
Breakdown risk rises if support fails with accelerating sell volume.
Relative strength versus sector peers remains neutral-to-slightly positive.

Latest indicator snapshot

Live technical and fundamental context, tuned for quick reads.

Supply Chain of XOMAP

Upstream / Downstream / Proxies

Upstream

Affitech SADay One BiopharmaceuticalsNASDAQ:DAWN Talphera, Inc.NASDAQ:TLPHDaré Bioscience, Inc.Pulmokine, Inc.Rezolute, Inc.NASDAQ:RZLTLava Therapeutics N.V.HilleVax, Inc.Turnstone Biologics Corp.Mural Oncology plcGossamer Bio, Inc.NASDAQ:GOSSChiesi Farmaceutici S.p.A.Alora Pharmaceuticals, LLC

Downstream

Roche Holding AG (Genentech)SWX:ROGDay One Biopharmaceuticals, Inc.NASDAQ:DAWN Organon & Co.NYSE:OGN Zevra Therapeutics, Inc.NASDAQ:ZVRA Talphera, Inc. / Alora PharmaceuticalsNASDAQ:TLPH Rezolute, Inc.NASDAQ:RZLT Pfizer Inc.NYSE:PFE Johnson & Johnson (Janssen)NYSE:JNJ Gossamer Bio, Inc. / Chiesi FarmaceuticiNASDAQ:GOSSTakeda Pharmaceutical Company LimitedTYO:4502Ligand Pharmaceuticals IncorporatedNASDAQ:LGND

Proxies

Royalty Pharma plcNASDAQ:RPRX Ligand Pharmaceuticals IncorporatedNASDAQ:LGNDDRI Healthcare TrustTSX:DHT.UN

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer